PROF. DR. RER. NAT. NORMA SELVE
Chief Development Officer
Prof. Dr. Norma Selve has more than 30 years of experience in big and medium-sized pharmaceutical and start-up biotech companies in the development of pharmaceuticals. She has direct experience and responsibility in the area of non-clinical drug development and managing regulatory affairs, particularly covering early stages of development from lead candidate selection (pharmacology, safety pharmacology, toxicology, kinetics / ADME) through entry into man and up to Phase II POC – in addition support of Phase III and post marketing phase IV line extension clinical studies, authority interactions and inspections.
In addition, Prof. Dr. Norma prepared several due diligences, and contributed to several IMPDs, INDs, and orphan drug applications, CTDs, CTAs and numerous direct face-to-face authority interactions. She headed 80 inter-department, as well as, inter-company project teams as the pre-clinical responsible with more than 50 projects reaching first-in-man status within the medical indications inflammation (e.g. RA, Asthma, COPD), immunology (e.g. MS, ALS, Thrombocytopenia), ZNS (e.g. pain, Parkinson’s disease, epilepsy, retinopathies, AMD), urology, dermatology and different types of cancer.
Prof. Dr. Norma Selva started her professional career in well-known Pharmaceutical companies like Sanofi-Synthelabo in France and Schwarz Pharma AG (Gemany / USA) as project leader and department heads in the area of pharmacology and toxicology. She then moved on in several senior roles as Chief Development Officer, Director Drug Development or Senior Vice President to several Biotech companies, such as Atugen, SR Pharma, NOXXON Pharma, or as external consultant for Affimed, Aptissen, Enterome CSL-Behring, Almirall Hermal, Fresenius Kabi, MEDA Pharma, Merck-Allergopharma, and the non-for-profit WHO organisation Medicines for Malaria Venture (MMV).
Prof. Dr. Norma Selve studied Biology at the Ruhr University in Bochum, made a bachelor degree, followed by a PhD in Physiological Chemistry and right afterwards as external a Habilitation and post-doctoral lecturing qualification in the experimental field in vivo pharmacology. In addition, she has acquired board certification as pharmacologist, toxicologist, DGPT and BTS, and ERT. Further, she served as an elected board member of the German Society of Experimental and Clinical Pharmacology and Toxicology (DGPT, 2003-2007).